Source: Newcomer
Meta's recruitment of Scale AI's Alexandr Wang and subsequent mega-deals signal a strategic shift: foundation model dominance now depends less on compute or data and more on acquiring specialized AI talent with proven track records in scaling. The pattern mirrors pharma's blockbuster drug wars, where the scarcest resource shifts from raw materials to the researchers who know how to synthesize them. For mid-tier AI companies and startups, the calculus is harsh—if Google, Meta, and OpenAI can simply buy the talent needed to leapfrog competitors, the foundation model race becomes a war of acquisition budgets rather than innovation speed.